Research programme: anticancer and antiviral immunotherapeutics - AvidBioticsAlternative Names: MICA-fusion proteins; Micacide™ proteins
Latest Information Update: 16 Sep 2013
$50 / €47 *
At a glance
- Originator AvidBiotics Corp.
- Class Immunoproteins; Recombinant fusion proteins
- Mechanism of Action Natural killer cell stimulants; T lymphocyte stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Viral infections
Most Recent Events
- 10 Sep 2013 Preclinical trials in Cancer in USA (Parenteral)
- 10 Sep 2013 Preclinical trials in Viral infections in USA (Parenteral)